Growth hormone research gets cleaner when the protocol begins at the axis level. Do you want to stimulate the GHRH side of the somatotropic axis? The ghrelin-receptor side? Both together? Or do you want to study a downstream effector like IGF1-LR3 instead of upstream signaling? Each of those is a different category decision before it becomes a compound decision.

That axis logic explains why Sermorelin, Tesamorelin, Ipamorelin, CJC/Ipamorelin Blend, and IGF1-LR3 all belong in the same roundup without being substitutes for one another.

Among GHRH analogs, Tesamorelin carries the strongest clinical visibility because of its stabilized design and regulatory history. Sermorelin remains valuable as the unmodified reference analog. Ipamorelin matters because it gives the GHRP side of the axis a more selective research tool. The blend matters because GHRH plus GHRP is often more interesting than either alone when the protocol studies synergy.

IGF1-LR3 belongs in the same roundup because some protocols want to bypass secretion logic entirely and look downstream at effector biology instead.

Choose Tesamorelin when duration, modification, and human clinical context matter most. Choose Sermorelin when you want the cleanest unmodified GHRH analog reference. Choose Ipamorelin when selectivity and ghrelin-receptor signaling are the core question. Choose the blend when the protocol is built around axis synergy. Choose IGF1-LR3 when the real question sits downstream of secretion.